Ozempic Is Making People Move Less

Do GLP-1 drugs like semaglutide quietly reduce how much you move — even as the weight comes off? New data from ENDO 2026, tracking 753 adults via Fitbit, says yes, and the implications for muscle retention are significant. Miles and Amara break down the study methodology and what the findings actually prove, explain how GLP-1 receptors interact with the brain's reward and motivation circuits to suppress both formal exercise and incidental daily movement, and lay out a concrete resistance training and protein protocol for active adults already on these medications. They also cover why step count in the first 60 to 90 days is a more honest metric than the scale. Strength, body composition, and long-term health are rarely just about weight — this Tuesday's episode makes the case for tracking all of it.